SeqLL Inc. Announces Pricing of Upsized $13 Million Initial Public Offering
27 Août 2021 - 2:41AM
SeqLL Inc. (“SeqLL” or the “Company”)
(NASDAQ:SQL; SQLLW), a development-stage life
sciences instrumentation and research services company engaged in
the development of scientific assets and novel intellectual
property across multiple “omics” fields, today announced the
pricing of its initial public offering of 3,060,000 shares of its
common stock and accompanying warrants to purchase up to 3,060,000
shares of common stock. Each share of common stock is being sold
together with one warrant to purchase one share of common stock
with an exercise price of $4.25 per share and an expiration date of
five years from the date of issuance at a combined offering price
of $4.25, for gross proceeds of approximately $13 million, before
deducting underwriting discounts and offering expenses. In
addition, SeqLL has granted the underwriters a 45-day option to
purchase up to an additional 459,000 shares of common stock and/or
warrants to purchase 459,000 shares of common stock to cover
over-allotments at the initial public offering price, less the
underwriting discount. All of the shares of common stock and
warrants are being offered by the Company.
The shares of common stock and warrants are
expected to begin trading on the Nasdaq Capital Market on August
27, 2021, under the symbols “SQL” and “SQLLW,” respectively.
The offering is expected to close on August 31, 2021, subject to
satisfaction of customary closing conditions.
The Company intends to use substantially all of
the net proceeds from the offering to expand its commercial
operations to support life sciences research and applications
development. The Company will prioritize select collaborative
research efforts to develop novel assets across multiple emerging
growth areas. These efforts will include, but are not limited to,
building additional sequencing instruments that utilize its tSMS
technology platform, manufacturing additional reagents and
consumables, and developing proprietary reagents for areas outside
its life sciences focus. The balance will be used for working
capital and other general corporate purposes.
Maxim Group LLC is acting as the sole
book-running manager in connection with the offering.
A registration statement on Form S-1 (File Nos.
333-254886 and 333-259097) was filed with the Securities and
Exchange Commission (“SEC”), which became effective on August 26,
2021. A final prospectus relating to the offering will be
filed with the SEC and will be available on the SEC's website at
http://www.sec.gov. The offering is being made only by means of a
prospectus forming part of the effective registration statement.
Electronic copies of the prospectus relating to this offering, when
available, may be obtained from Maxim Group LLC, 300 Park Avenue,
16th Floor, New York, New York 10022, at (212) 895-3745. Before
investing in this offering, interested parties should read in its
entirety the registration statement that the Company has filed with
the SEC, which provides additional information about the Company
and this offering.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About SeqLL:SeqLL Inc.
(“SeqLL”) is a development-stage life sciences instrumentation and
research services company engaged in the development of scientific
assets and novel intellectual property across multiple “omics”
fields. The Company intends to leverage their expertise with True
Single Molecule Sequencing (“tSMS®”) technology to enable
researchers and clinicians to contribute major advancements to
scientific research and development by accelerating one’s
understanding of the molecular mechanisms of disease and
fundamental biological processes.
Forward Looking Statements:This
press release contains certain forward-looking statements,
including those relating to the regarding the anticipated timing of
completion of the offering and other statements that are predictive
in nature. Forward-looking statements are based on the Company's
current expectations and assumptions. The Private Securities
Litigation Reform Act of 1995 provides a safe-harbor for
forward-looking statements. These statements may be identified by
the use of forward-looking expressions, including, but not limited
to, "expect," "anticipate," "intend," "plan," "believe,"
"estimate," "potential," "predict," "project," "should," "would"
and similar expressions and the negatives of those terms.
Prospective investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this presentation. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events or otherwise. Important factors that
could cause actual results to differ materially from those in the
forward-looking statements are set forth in the Company's filings
with the Securities and Exchange Commission, including its
registration statement on Form S-1, as amended from time to time,
under the caption "Risk Factors."
Contact:John
Kennedyinvestors@seqll.com
SeqLL (NASDAQ:SQLLW)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
SeqLL (NASDAQ:SQLLW)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024